{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:07:54Z","timestamp":1791994074191,"version":"4.4.0"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.pnpbp.2020.110163","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T20:04:10Z","timestamp":1604347450000},"page":"110163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["CB1 allosteric modulators and their therapeutic potential in CNS disorders"],"prefix":"10.1016","volume":"106","author":[{"given":"Catharine A.","family":"Mielnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent M.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2020.110163_bb0005","article-title":"FDA briefing document, NDA 21-288. Zimulit (rimonabant) tablets 20 mg","author":"Administration","year":"2007","journal-title":"U.S.Food Drug Adm"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0010","doi-asserted-by":"crossref","first-page":"12070","DOI":"10.1074\/jbc.M111.316463","article-title":"Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1\/2 kinase activation","volume":"287","author":"Ahn","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jnc.12115","article-title":"Profiling two indole-2-carboxamides for allosteric modulation of the CB1 receptor","volume":"124","author":"Ahn","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0020","first-page":"111","article-title":"Simplified guideline for prescribing medical cannabinoids in primary care","volume":"64","author":"Allan","year":"2018","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0025","doi-asserted-by":"crossref","DOI":"10.1111\/j.1476-5381.2010.00729.x","article-title":"CB 2: a cannabinoid receptor with an identity crisis","author":"Atwood","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/mol.112.080879","article-title":"CB1 receptor allosteric modulators display both agonist and signaling pathway specificity","volume":"83","author":"Baillie","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0035","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hipo.22272","article-title":"Elevation of endogenous anandamide impairs LTP, learning, and memory through CB1 receptor signaling in mice","volume":"24","author":"Basavarajappa","year":"2014","journal-title":"Hippocampus"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0040","doi-asserted-by":"crossref","first-page":"36944","DOI":"10.1074\/jbc.M112.382481","article-title":"Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB 1 receptors","volume":"287","author":"Bauer","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(01)46057-0","article-title":"Neurosteroids: beginning of the story","volume":"46","author":"Baulieu","year":"2001","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0050","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","article-title":"Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated Glia in Alzheimer\u2019s disease brains","volume":"23","author":"Benito","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0055","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1016\/j.bmc.2017.10.015","article-title":"Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor","volume":"25","author":"Bertini","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0079-6123(08)62096-8","article-title":"Allosteric regulation of muscarinic receptors","volume":"109","author":"Birdsall","year":"1996","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0065","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/mp.2017.4","article-title":"Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice","volume":"22","author":"Busquets-Garcia","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0070","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FBP.0b013e32833b33c5","article-title":"Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors","volume":"21","author":"Casarotto","year":"2010","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0075","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/bph.12329","article-title":"Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action","volume":"170","author":"Cawston","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0080","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/acs.jmedchem.5b00579","article-title":"Distinct temporal fingerprint for cyclic adenosine monophosphate (cAMP) signaling of indole-2-carboxamides as allosteric modulators of the cannabinoid receptors","volume":"58","author":"Cawston","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0085","doi-asserted-by":"crossref","DOI":"10.1517\/13543784.16.7.951","article-title":"Targeting cannabinoid agonists for inflammatory and neuropathic pain","author":"Cheng","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0090","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0095","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nrd746","article-title":"Allosteric binding sites on cell-surface receptors: novel targets for drug discovery","volume":"1","author":"Christopoulos","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/pr.54.2.323","article-title":"G protein-coupled receptor allosterism and complexing","volume":"54","author":"Christopoulos","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0022-3565(25)11216-0","article-title":"Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents","volume":"260","author":"Compton","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1124\/mol.119.115956","article-title":"A biased view of \u03bc-opioid receptors?","volume":"96","author":"Conibear","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pnpbp.2012.02.009","article-title":"Cannabinoid receptors: nomenclature and pharmacological principles","volume":"38","author":"Console-Bram","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2017.140","article-title":"Sex-dependent effects of cannabis and cannabinoids: a translational perspective","author":"Cooper","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0130","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despr\u00e9s","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2018.115","article-title":"New approaches and challenges to targeting the endocannabinoid system","author":"Di Marzo","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.69","article-title":"Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in rats","volume":"2","author":"Ding","year":"2014","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/03602532.2018.1428342","article-title":"Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity","volume":"50","author":"Dopart","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0155","doi-asserted-by":"crossref","first-page":"100574","DOI":"10.1016\/j.curtheres.2019.100574","article-title":"Structural optimization of the diarylurea PSNCBAM-1, an allosteric modulator of cannabinoid receptor 1","volume":"92","author":"Dopart","year":"2020","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0160","article-title":"Targeting endocannabinoid signaling: FAAH and MAG Lipase inhibitors","author":"van Egmond","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0165","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/(SICI)1098-2299(199702)40:2<193::AID-DDR9>3.0.CO;2-G","article-title":"Allosteric binding sites on muscarinic receptors","volume":"40","author":"Ellis","year":"1997","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/bph.12492","article-title":"The influence of cannabinoids on generic traits of neurodegeneration","author":"Fagan","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0175","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12035-016-9697-5","article-title":"Role of the endocannabinoid system in the pathophysiology of Schizophrenia","volume":"54","author":"Fakhoury","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0180","doi-asserted-by":"crossref","first-page":"33873","DOI":"10.1074\/jbc.M112.352328","article-title":"A key agonist-induced conformational change in the cannabinoid receptor CB1 is blocked by the allosteric ligand Org 27569","volume":"287","author":"Fay","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0185","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1073\/pnas.1500895112","article-title":"Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1","volume":"112","author":"Fay","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0190","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fphar.2020.00359","article-title":"Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors","volume":"11","author":"Finlay","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0195","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neuron.2017.03.016","article-title":"Allosteric modulation of GPCRS: new insights and potential utility for treatment of Schizophrenia and other CNS disorders","volume":"94","author":"Foster","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0200","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1021\/acs.jmedchem.8b00368","article-title":"Identification of the first synthetic allosteric modulator of the CB 2 receptors and evidence of its efficacy for neuropathic pain relief","volume":"62","author":"Gado","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","article-title":"Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations","volume":"232","author":"Galiegue","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0210","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/FBP.0000000000000027","article-title":"In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569","volume":"25","author":"Gamage","year":"2014","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0215","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1089\/can.2016.0028","article-title":"CB1 allosteric modulator Org27569 is an antagonist\/inverse agonist of ERK1\/2 signaling","volume":"1","author":"Gamage","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0220","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2017.08.008","article-title":"The great divide: separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators","volume":"125","author":"Gamage","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0225","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1021\/acs.jmedchem.9b01142","article-title":"Application of fluorine- and nitrogen-walk approaches: defining the structural and functional diversity of 2-phenylindole class of Cannabinoid 1 receptor positive allosteric modulators","volume":"63","author":"Garai","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0230","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1093\/nar\/18.23.7142","article-title":"Nucleotide sequence of a human cannabinoid receptor cDNA","volume":"18","author":"G\u00e9rard","year":"1990","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0235","doi-asserted-by":"crossref","first-page":"7758","DOI":"10.1021\/jm501042u","article-title":"Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1)","volume":"57","author":"German","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/157015907781695946","article-title":"Allosteric modulation of muscarinic acetylcholine receptors","volume":"5","author":"Gregory","year":"2007","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0245","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1016\/j.bmcl.2016.08.018","article-title":"Development of indole sulfonamides as cannabinoid receptor negative allosteric modulators","volume":"26","author":"Greig","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0250","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/187152709789824660","article-title":"The endocannabinoid system and pain","volume":"8","author":"Guindon","year":"2012","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.tplants.2020.05.005","article-title":"Phytocannabinoids: origins and biosynthesis","author":"G\u00fclck","year":"2020","journal-title":"Trends Plant Sci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0260","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/j.1460-9568.2007.05476.x","article-title":"Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission","volume":"25","author":"Haller","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0265","doi-asserted-by":"crossref","first-page":"20588","DOI":"10.1073\/pnas.0706980105","article-title":"Hemopressin is an inverse agonist of CB1 cannabinoid receptors","volume":"104","author":"Heimann","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0270","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2017.162","article-title":"Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder","author":"Hill","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0275","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.bjp.0707347","article-title":"PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB 1 receptors with hypophagic effects in rats","volume":"152","author":"Horswill","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0280","series-title":"Advances in Pharmacology","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.apha.2017.03.007","article-title":"CB1 and CB2 receptor pharmacology","author":"Howlett","year":"2017"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/S0026-895X(25)10219-8","article-title":"Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs","volume":"29","author":"Howlett","year":"1986","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/S0026-895X(25)13196-9","article-title":"Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model","volume":"33","author":"Howlett","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0295","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2016.10.004","article-title":"Crystal structure of the human cannabinoid receptor CB1","volume":"167","author":"Hua","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0300","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nature23272","article-title":"Crystal structures of agonist-bound human cannabinoid receptor CB 1","volume":"547","author":"Hua","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0305","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.01.008","article-title":"Activation and signaling mechanism revealed by Cannabinoid receptor-Gi complex structures","volume":"180","author":"Hua","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0310","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0026-895X(25)09974-2","article-title":"Identification of allosteric antagonists of receptor-guanine nucleotide-binding protein interactions","volume":"37","author":"Huang","year":"1990","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0315","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1038\/npp.2015.148","article-title":"A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects","volume":"40","author":"Ignatowska-Jankowska","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0320","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1089\/can.2018.0046","article-title":"Exploring 6-Azaindole and 7-Azaindole rings for developing cannabinoid receptor 1 allosteric modulators","volume":"3","author":"Immadi","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0325","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.biopsych.2009.09.024","article-title":"Brain Cannabinoid CB2 receptor in Schizophrenia","volume":"67","author":"Ishiguro","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/mol.118.112854","article-title":"Pyrimidinyl biphenylureas act as allosteric modulators to activate cannabinoid receptor 1 and initiate \u03b2-arrestin-dependent responses","volume":"95","author":"Jagla","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0335","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.drugalcdep.2014.08.004","article-title":"Effects of the cannabinoid CB1 receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats","volume":"143","author":"Jing","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0340","doi-asserted-by":"crossref","first-page":"10422","DOI":"10.1523\/JNEUROSCI.1850-08.2008","article-title":"Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats","volume":"28","author":"Jones","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0345","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/npp.2011.199","article-title":"Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia","volume":"37","author":"Jones","year":"2012","journal-title":"Neuropsychopharmacol. Rev."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0350","first-page":"1","article-title":"Endocannabinoid system components as potential biomarkers in psychiatry","volume":"11","author":"Jurado-barba","year":"2020","journal-title":"Article"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0355","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/JCP.0b013e318204825b","article-title":"Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study","volume":"31","author":"Kelly","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0360","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/jpet.110.173948","article-title":"Functional selectivity and biased receptor signaling","volume":"336","author":"Kenakin","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0365","first-page":"294","article-title":"Cannabinoid receptors in the central nervous system: their signaling and roles in disease","volume":"10","author":"Kendall","year":"2016","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0370","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40429-016-0114-y","article-title":"Sex effects of Marijuana on brain structure and function","volume":"3","author":"Ketcherside","year":"2016","journal-title":"Curr. Addict. Reports"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0375","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/mol.115.099192","article-title":"Biased agonism and biased allosteric modulation at the CB1 Cannabinoid receptor","volume":"88","author":"Khajehali","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0380","first-page":"5","article-title":"Allosteric and biased G protein-coupled receptor signaling regulation: potentials for new therapeutics","author":"Khoury","year":"2014","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0385","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1021\/jm5000112","article-title":"Optimization of chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1)","volume":"57","author":"Khurana","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0390","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1021\/acs.jmedchem.6b01448","article-title":"Pyrimidinyl biphenylureas: identification of new lead compounds as allosteric modulators of the cannabinoid receptor CB1","volume":"60","author":"Khurana","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0395","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuropharm.2017.05.018","article-title":"Modulation of CB1 cannabinoid receptor by allosteric ligands: pharmacology and therapeutic opportunities","volume":"124","author":"Khurana","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0400","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.euroneuro.2013.10.008","article-title":"The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain","volume":"24","author":"Klauke","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0405","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/bph.15004","article-title":"Morphine-induced respiratory depression is independent of \u03b2-arrestin2 signalling","volume":"177","author":"Kliewer","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0410","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cell.2018.11.040","article-title":"Structure of a signaling cannabinoid receptor 1-G protein complex","volume":"176","author":"Krishna Kumar","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0415","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1021\/jm980363y","article-title":"Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists","volume":"42","author":"Lan","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0420","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0435","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1021\/acschemneuro.6b00310","article-title":"Enantiospecific allosteric modulation of cannabinoid 1 receptor","volume":"8","author":"Laprairie","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0425","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1021\/acschemneuro.6b00041","article-title":"Mapping cannabinoid 1 receptor allosteric site(s): critical molecular determinant and signaling profile of GAT100, a novel, potent, and irreversibly binding probe","volume":"7","author":"Laprairie","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0430","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2016.10.005","article-title":"Cannabinoid receptor ligand bias: implications in the central nervous system","volume":"32","author":"Laprairie","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2019.03.033","article-title":"Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington\u2019s disease in the R6\/2 mouse model","volume":"151","author":"Laprairie","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0445","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-009-1506-7","article-title":"The future of endocannabinoid-oriented clinical research after CB 1 antagonists","author":"Le Foll","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamapsychiatry.2019.2508","article-title":"Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits","volume":"76","author":"Legge","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0455","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-17796-y","article-title":"Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0465","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1017\/S1461145709990605","article-title":"A behavioural comparison of acute and chronic 9- tetrahydrocannabinol and cannabidiol in C57BL\/6JArc mice","volume":"13","author":"Long","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0470","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0026-895X(25)13215-X","article-title":"Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells","volume":"44","author":"Mackie","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0475","doi-asserted-by":"crossref","first-page":"7965","DOI":"10.1021\/jm4009828","article-title":"Structure-activity relationship study of indole-2-carboxamides identifies a potent allosteric modulator for the cannabinoid receptor 1 (CB1)","volume":"56","author":"Mahmoud","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2018.09.013","article-title":"Role of the endocannabinoid system in drug addiction","author":"Manzanares","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0485","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.npp.1301118","article-title":"N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both Cannabinoid and vanilloid receptors","volume":"32","author":"Marinelli","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0490","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0091-3057(91)90349-7","article-title":"Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs","volume":"40","author":"Martin","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0495","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105159","article-title":"Allosteric modulation of G protein-coupled receptors","volume":"47","author":"May","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0505","series-title":"Nabilone for Chronic Pain Management: A Review of Clinical Effectiveness and Guidelines \u2013 An Update, Nabilone for Chronic Pain Management: A Review of Clinical Effectiveness and Guidelines \u2013 An Update","author":"McGolrick","year":"2018"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0510","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0515","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pbb.2013.04.011","article-title":"Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054","volume":"109","author":"McLaughlin","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0520","doi-asserted-by":"crossref","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and \u03949-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic revie","author":"McPartland","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0525","doi-asserted-by":"crossref","first-page":"112606","DOI":"10.1016\/j.ejmech.2020.112606","article-title":"PSNCBAM-1 analogs: structural evolutions and allosteric properties at cannabinoid CB1 receptor","volume":"203","author":"Meini","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0530","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1523\/JNEUROSCI.4503-03.2004","article-title":"Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors","volume":"24","author":"Melis","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0535","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0540","first-page":"9.59.1","article-title":"Cannabinoid-induced tetrad in mice","volume":"2017","author":"Metna-Laurent","year":"2017","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0545","series-title":"A Novel Allosteric Modulator of the Cannabinoid CB1 Receptor Ameliorates Hyperdopaminergia Endophenotypes in Rodent Models. Neuropsychopharmacol","author":"Mielnik","year":"2020"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","author":"Millar","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0555","article-title":"The heavy economic burden of schizophrenia","volume":"33","author":"Miller","year":"2016","journal-title":"Psychiatr. Times"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0560","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jamapsychiatry.2019.0970","article-title":"Measuring disturbance of the endocannabinoid system in psychosis: a systematic review and meta-analysis","volume":"76","author":"Minichino","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0565","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.phrs.2017.11.019","article-title":"Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons","volume":"129","author":"Mitjavila","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0570","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/S1516-44462009000200012","article-title":"The psychiatric side-effects of rimonabant","volume":"31","author":"Moreira","year":"2009","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0575","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejphar.2005.02.040","article-title":"Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice","volume":"512","author":"Moreira","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0580","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2015.166","article-title":"Neurobiological interactions between stress and the endocannabinoid system","author":"Morena","year":"2016","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0585","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172840","article-title":"In vivo evaluation of the CB1 allosteric modulator LDK1258 reveals CB1-receptor independent behavioral effects","volume":"190","author":"Mustafa","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0595","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00001756-199701200-00023","article-title":"Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat","volume":"8","author":"Navarro","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0600","article-title":"The loss of NMDAR-dependent LTD following cannabinoid self-administration is restored by positive allosteric modulation of CB1 receptors","author":"Neuhofer","year":"2019","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0605","doi-asserted-by":"crossref","DOI":"10.1177\/070674370605100803","article-title":"The metabolic effects of antipsychotic medications","author":"Newcomer","year":"2006","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0610","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.bmc.2015.02.058","article-title":"Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators","volume":"23","author":"Nguyen","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0615","doi-asserted-by":"crossref","first-page":"7410","DOI":"10.1021\/acs.jmedchem.7b00707","article-title":"Novel diarylurea based allosteric modulators of the cannabinoid CB1 receptor: evaluation of importance of 6-pyrrolidinylpyridinyl substitution","volume":"60","author":"Nguyen","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0620","doi-asserted-by":"crossref","DOI":"10.1002\/med.21418","article-title":"Allosteric modulation: an alternate approach targeting the cannabinoid CB1 receptor","author":"Nguyen","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0625","doi-asserted-by":"crossref","DOI":"10.1002\/med.21418","article-title":"Allosteric modulation: an alternate approach targeting the Cannabinoid CB1 receptor","author":"Nguyen","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0630","doi-asserted-by":"crossref","first-page":"9806","DOI":"10.1021\/acs.jmedchem.9b01161","article-title":"Synthesis and pharmacological evaluation of 1-phenyl-3-thiophenylurea derivatives as cannabinoid type-1 receptor allosteric modulators","volume":"62","author":"Nguyen","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0635","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1021\/acschemneuro.8b00396","article-title":"Diarylureas containing 5-membered heterocycles as CB1 receptor allosteric modulators: design, synthesis, and pharmacological evaluation","volume":"10","author":"Nguyen","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0640","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2174\/1568026619666190708164841","article-title":"Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: current approaches for therapeutics development","volume":"19","author":"Nguyen","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0645","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000100778","article-title":"Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain","volume":"54","author":"Onaivi","year":"2007","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0650","series-title":"Annals of the New York Academy of Sciences","first-page":"514","article-title":"Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain","author":"Onaivi","year":"2006"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0655","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/npp.2011.34","article-title":"Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice","volume":"36","author":"Ortega-Alvaro","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0660","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neulet.2009.12.050","article-title":"Aspirin-triggered lipoxin induces CB1-dependent catalepsy in mice","volume":"470","author":"Pamplona","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0665","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neulet.2009.12.050","article-title":"Aspirin-triggered lipoxin induces CB1-dependent catalepsy in mice","volume":"470","author":"Pamplona","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0670","doi-asserted-by":"crossref","first-page":"21134","DOI":"10.1073\/pnas.1202906109","article-title":"Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor","volume":"109","author":"Pamplona","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0675","doi-asserted-by":"crossref","first-page":"11244","DOI":"10.1523\/JNEUROSCI.1040-11.2011","article-title":"Extracellular signal-regulated kinase signaling in the ventral tegmental area mediates cocaine-induced synaptic plasticity and rewarding effects","volume":"31","author":"Pan","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0680","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/07391102.2019.1567384","article-title":"Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist","volume":"38","author":"Pandey","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0685","doi-asserted-by":"crossref","DOI":"10.1007\/3-540-26573-2_1","article-title":"Pharmacological actions of cannabinoids","volume":"1\u201351","author":"Pertwee","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2020.110163_bb0690","article-title":"The pharmacology of cannabinoid receptors and their ligands: an overview","volume":"30","author":"Pertwee","year":"2006","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0695","doi-asserted-by":"crossref","DOI":"10.1124\/pr.110.003004","article-title":"International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2","author":"Pertwee","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0700","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1021\/jm201485c","article-title":"Indole-2-carboxamides as allosteric modulators of the cannabinoid CB 1 receptor","volume":"55","author":"Piscitelli","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0705","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0710","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/mol.105.016162","article-title":"Allosteric modulation of the cannabinoid CB1 receptor","volume":"68","author":"Price","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0715","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2174\/187152712801661310","article-title":"Potential control of multiple sclerosis by cannabis and the endocannabinoid system","volume":"11","author":"Pryce","year":"2012","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0720","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejmech.2016.05.044","article-title":"Synthesis and biological evaluation of indole-2-carboxamides bearing photoactivatable functionalities as novel allosteric modulators for the cannabinoid CB1 receptor","volume":"121","author":"Qiao","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0725","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.pharep.2018.01.010","article-title":"Effects of central RVD-hemopressin(\u03b1) administration on anxiety, feeding behavior and hypothalamic neuromodulators in the rat","volume":"70","author":"Recinella","year":"2018","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0730","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.pharep.2018.01.010","article-title":"Effects of central RVD-hemopressin(\u03b1) administration on anxiety, feeding behavior and hypothalamic neuromodulators in the rat","volume":"70","author":"Recinella","year":"2018","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0735","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0014-5793(94)00773-X","article-title":"SR141716A, a potent and selective antagonist of the brain cannabinoid receptor","volume":"350","author":"Rinaldi-Carmona","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0740","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/dc08-0386","article-title":"SERENADE: The study evaluating rimonabant efficacy in drug-naive diabetic patients: Effects of monotherapy with rimonabant, the first selective CB 1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes","volume":"31","author":"Rosenstock","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0745","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.2174\/138161212802884690","article-title":"Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies","volume":"18","author":"Roser","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0750","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tips.2016.12.004","article-title":"Cannabidiol claims and misconceptions","volume":"38","author":"Russo","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0755","article-title":"Dynamic changes to the endocannabinoid system in models of chronic pain","author":"Sagar","year":"2012","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0760","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/anie.201708764","article-title":"Multiple binding sites contribute to the mechanism of mixed agonistic and positive allosteric modulators of the cannabinoid CB1 receptor","volume":"57","author":"Saleh","year":"2018","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0765","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/432607","article-title":"Rimonabant: from RIO to Ban","volume":"2011","author":"Sam","year":"2011","journal-title":"J. Obes."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0770","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/can.2019.0016","article-title":"Absence of entourage: terpenoids commonly found in cannabis sativa do not modulate the functional activity of \u03949-THC at human CB1 and CB2 receptors","volume":"4","author":"Santiago","year":"2019","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0775","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","article-title":"Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study","volume":"368","author":"Scheen","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0780","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1073\/pnas.81.17.5335","article-title":"Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes","volume":"81","author":"Serhan","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0785","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature20613","article-title":"High-resolution crystal structure of the human CB1 cannabinoid receptor","volume":"540","author":"Shao","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0790","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41589-019-0387-2","article-title":"Structure of an allosteric modulator bound to the CB1 cannabinoid receptor","volume":"15","author":"Shao","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0795","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1074\/jbc.M113.478495","article-title":"Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling","volume":"289","author":"Shore","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0800","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.biopsych.2017.06.032","article-title":"Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence","volume":"84","author":"Slivicki","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0805","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.00054","article-title":"Positive allosteric modulation of cb1 cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without enhancing morphine- induced dependence or reward","volume":"13","author":"Slivicki","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0810","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.phrs.2015.07.017","article-title":"Aiming for allosterism: evaluation of allosteric modulators of CB1 in a neuronal model","volume":"99","author":"Straiker","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0815","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/mol.118.111864","article-title":"cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons","volume":"94","author":"Straiker","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0820","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1074\/jbc.274.5.2794","article-title":"Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor: structure-activity relationship of 2-arachidonoylglycerol, ether- linked analogues, and related compounds","volume":"274","author":"Sugiura","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0825","doi-asserted-by":"crossref","DOI":"10.1098\/rsos.190574","article-title":"Contrasting characteristic behaviours among common laboratory mouse strains","volume":"6","author":"Sultana","year":"2019","journal-title":"R. Soc. Open Sci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0830","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1046\/j.1460-9568.2002.02041.x","article-title":"Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids","volume":"15","author":"Szabo","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0835","series-title":"Cannaboinoid Antiemetic Therapy","author":"Taylor","year":"2018"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0840","doi-asserted-by":"crossref","DOI":"10.3390\/genes11040431","article-title":"Cannabinoid control of olfactory processes: The where matters","author":"Terral","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0845","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2174\/1389557054368772","article-title":"CB1 cannabinoid receptor ligands","volume":"5","author":"Thakur","year":"2005","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0850","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/bph.14440","article-title":"Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors","volume":"176","author":"Tham","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0855","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0860","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1126\/science.1243985","article-title":"Pregnenolone can protect the brain from cannabis intoxication","volume":"343","author":"Vall\u00e9e","year":"2014","journal-title":"Science (80)"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0865","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0870","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Neuroscience: Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science (80)"},{"key":"10.1016\/j.pnpbp.2020.110163_bb0875","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pbb.2005.01.029","article-title":"Endocannabinoid system and stress and anxiety responses","volume":"81","author":"Viveros","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0880","doi-asserted-by":"crossref","first-page":"52908","DOI":"10.1155\/2007\/52908","article-title":"Endocannabinoid system and synaptic plasticity: implications for emotional responses","volume":"2007","author":"Viveros","year":"2007","journal-title":"Neural Plast."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0885","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0014-2999(03)01856-9","article-title":"Cannabinoid pharmacological properties common to other centrally acting drugs","volume":"471","author":"Wiley","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0890","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2377-6-12","article-title":"COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord","volume":"6","author":"Yiangou","year":"2006","journal-title":"BMC Neurol."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0895","article-title":"Integrating endocannabinoid signaling in the regulation of anxiety and depression","author":"Yin","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.pnpbp.2020.110163_bb0900","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/adb.12367","article-title":"Expression of functional cannabinoid CB2 receptor in VTA dopamine neurons in rats","volume":"22","author":"Zhang","year":"2017","journal-title":"Addict. Biol."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584620304796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584620304796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:55:38Z","timestamp":1759521338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584620304796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":179,"alternative-id":["S0278584620304796"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110163","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CB1 allosteric modulators and their therapeutic potential in CNS disorders","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110163"}}